Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nycomed sues Glenmark over ANDA for fluticasone lotion

This article was originally published in Scrip

Executive Summary

Nycomedhas filed a patent infringement suit in the eastern district court of New York against Glenmark Generics' US subsidiary over the latter's ANDA for fluticasone propionate 0.05% lotion. The product is a generic version of Nycomed's Cutivate lotion, used for inflammatory and pruritic manifestations of atopic dermatitis. Glenmark believes it may be the first applicant to have filed an ANDA for this product with a paragraph IV certification. Glenmark will be entitled to a 180-day marketing exclusivity, should it successfully challenge Nycomed's patent. Cutivate 0.05% lotion reported annual sales of about $33 million in the US, IMS sales data to the end of September show.

You may also be interested in...

Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon

Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.

Merck KGaA Exec On Innovating Vaccine Manufacturing To Tackle Outbreaks

The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.

Rivals Challenge Nintedanib In India

Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts